“Needham Reaffirms ‘Buy’ Rating for Cellebrite DI on May 17, 2023”.
May 19, 2023
Trending News 🌥️
On May 17, 2023, Needham reaffirmed their Buy rating on Cellebrite ($NASDAQ:CLBT) DI according to Fintel. Cellebrite DI is a digital intelligence company which provides data extraction, analysis and transfer solutions to law enforcement, military and intelligence, government and corporate customers. The company offers digital forensics, mobile lifecycle, cyber intelligence and enterprise mobility solutions and services. The solutions help customers extract data from mobile devices during investigations and facilitate the secure transfer of data between different devices.
The company also provides a range of consulting services such as Digital Forensics Training, Mobile Device Analysis and Investigations, Cyber Threat Intelligence and Digital Forensics. With its broad range of services, Cellebrite DI is well-positioned to continue to provide customers with the digital intelligence solutions they need.
Price History
The stock opened the day at a price of $5.5 and closed at $5.4, down by 2.2% from the prior closing price of $5.6. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cellebrite Di. More…
| Total Revenues | Net Income | Net Margin |
| 279.5 | 20.07 | 8.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cellebrite Di. More…
| Operations | Investing | Financing |
| 43.59 | -81.89 | 13.07 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cellebrite Di. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 412.69 | 373.33 | 0.2 |
Key Ratios Snapshot
Some of the financial key ratios for Cellebrite Di are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 16.3% | – | 1.1% |
| FCF Margin | ROE | ROA |
| 12.8% | 3.5% | 0.5% |
Analysis
At GoodWhale, we recently conducted an analysis of CELLEBRITE DI‘s wellbeing. The results of our research indicated that CELLEBRITE DI is a high risk investment in terms of both its financial and business aspects. In particular, we identified two risk warnings in the cash flow statement and financial journal that require further investigation. If you’re interested in learning more about these risks, we encourage you to register with GoodWhale for access to additional information. With our expertise and comprehensive analysis, we are confident we can guide you towards making informed decisions about potential investments. More…
Peers
The mobile phone forensics market is expected to grow from USD 1.71 billion in 2019 to USD 2.34 billion by 2024, at a CAGR of 6.1% during the forecast period. The major players operating in this market are Cellebrite DI Ltd (Israel), Flect Co Ltd (Japan), Qing Cloud Technologies Corp (China), Gofore PLC (Finland), among others.
– Flect Co Ltd ($TSE:4414)
Flect Co Ltd is a leading provider of information technology services. It has a market cap of 6.36B as of 2022 and a return on equity of 19.11%. The company offers a wide range of services including cloud computing, big data, enterprise software, and more. It has a strong presence in the Asia-Pacific region and is expanding its operations globally.
– Qing Cloud Technologies Corp ($SHSE:688316)
Qing Cloud Technologies Corp is a Chinese cloud computing company with a market cap of 1.42B as of 2022. The company has a Return on Equity of -37.3%. Qing Cloud Technologies Corp provides cloud computing services to businesses and government organizations. The company offers public cloud, private cloud, and hybrid cloud solutions.
– Gofore PLC ($LTS:0CXS)
Gofore Plc is a Finnish consulting company that offers digitalization, enterprise resource planning, and customer relationship management services. Its customers are large and medium-sized organizations in both the private and public sectors. Gofore has a market cap of 332.62M as of 2022 and a Return on Equity of 14.21%. The company has been growing rapidly and has been profitable for many years.
Summary
Investors looking to invest in Cellebrite DI can take heart from the recent recommendation from Needham. On May 17, 2023, the firm reiterated its Buy recommendation on the stock, citing the company’s strong fundamentals and potential for growth. Analysts expect Cellebrite DI to benefit from the strong demand for its digital intelligence solutions, as well as its competitive advantages in automation, analytics and data integration, which will support its long-term growth prospects. Investors should continue to monitor the stock’s performance, as well as any new developments in the industry.
Related Posts
Recent Posts
